DexCom Stock: The Growth Thesis Still Needs To Be Proven (NASDAQ:DXCM)
· seekingalpha.com
DexCom (DXCM) faces GLP-1 disruption as it targets non-insulin Type 2 CGM growth. Read here for a detailed invesment analysis.
DexCom ( DXCM ) is navigating an important transition because the company's growth has been driven by patients with insulin-treated diabetes, but the rapid adop...